Email this article Current possibilities of correcting subchondral bone resorption as a major pathogenetic factor for progressive osteoarthrosis
- Authors: Naumov AV1
-
Affiliations:
- ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
- Issue: Vol 86, No 1 (2014)
- Pages: 60-65
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31434
- ID: 31434
Cite item
Full Text
Abstract
The paper considers the current pathogenesis, by choosing the actual targets of pharmacotherapy with available drugs. It reflects the cytokine mechanisms responsible for lesion of the synovial membranes, cartilage, and subchondral bone. Particular emphasis is laid on the role of chondroitin sulfate, glucosamine, vitamin D3 as drugs that affect the key components of pathogenesis, including the volume of resorptive cavities in the subchondral bone.
Full Text
##article.viewOnOriginalSite##About the authors
A V Naumov
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
Email: nanton78@gmail.com
References
- Fortin M., Stewart M., Poitras M.-E. et al. Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. Ann Fam Med 2012; 10 (2): 142-151.
- Long Term Conditions Compendium of Information: Third Edition. Department of Health UK, 2012.
- Haugen I.K. Abstracts from OARSI. Osteoarthritis Cartilage 2013; 289.
- Zhang W., Nuki G., Moskowitz R.W. et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18 (4): 476-499.
- Wildi L., Raynauld J., Martel-Pelletier J. et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70: 982-989.
- Michel B.A., Stucki G., Frey D. et al. Chondroitin 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779-786.
- Tat S.K., Pelletier J.-P., Vergés J. et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther 2007, 9: R117.
- Pelletier J.-P. Chondroitin sulfate may reduce total knee replacement in 12-month multicenter clinical trial in knee osteoarthritis: results from 4-year observation. EULAR, ACR 2012.
